Fig. 2

KDELR2 functions as an oncogene in BCa. A-B Verification of KDELR2 expression in clinical tissues by qRT-PCR (normal, n = 24; tumor, n = 24) and immunohistochemical (IHC) staining (200x, 400x). C Detection of KDELR2 expression by western blot analysis in cell lines (n = 3). D, G Identification of knockdown or overexpression efficiency of KDELR2 by qRT-PCR and western blot analysis (n = 3). E, H Proliferation analysis of UMUC3 or T24 cells in the control (con) and siKDELR2-3 or KDELR2-overexpressing (ov) group (n = 4). (F, I) Migration and invasion (200x) of BCa cells in the control and siKDELR2-3 or KDELR2-overexpressing group (n = 3). p < 0.05, *; p < 0.01, **; p < 0.001, ***; p < 0.0001, ****